PlumX Metrics
Embed PlumX Metrics

A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate

Future Oncology, ISSN: 1479-6694, Vol: 9, Issue: 10, Page: 1437-1442
2013
  • 4
    Citations
  • 0
    Usage
  • 24
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Aim: We report our experience with eribulin mesylate in a pancytopenic heavily pretreated patient with multiple bone metastases and bone marrow infiltration from breast cancer. Methods: Eribulin mesylate was given at 1.4 mg/mon day 1 and 8 every 3 weeks for a total of 11 courses. Results: After seven cycles, evaluation with a bone marrow biopsy showed a large decrease of neoplastic involvement with substitution of osteolitic lesions for the osteoaddensant type. No unexpected acute toxicity was observed. Conclusion: To our knowledge, this represents the first report of bone marrow metastases from breast cancer treated with eribulin mesylate that obtained an improvement of hematopoietic values with an acceptable profile of tolerability and good compliance for the subject. © 2013 Future Medicine Ltd.

Bibliographic Details

Pashaj, Etleva; Cortesi, Laura; Proietto, Manuela; Bonacorsi, Goretta; Liardo, Eliana; Federico, Massimo

Informa UK Limited

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know